TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25303024

Group type: EXPERIMENTAL
Intervention: Non-ablative fractional photothermolysis (FP) using a fractional 1550-nm ytterbium/erbium fibre laser, delivered four times at 4-week intervals.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-ablative fractional photothermolysis (FP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (lesions on the other side of the body)
Number of subjects: 30
Study: 23504039

Group type: EXPERIMENTAL
Intervention: toltrazuril (MTol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (NegC)
Number of subjects: 40
Study: 21402547

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17849380

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy with postoperative anastomotic leakage
Number of subjects: 908

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 908
Study: 16598975

Group type: EXPERIMENTAL
Intervention: Augmented recession of the medial rectus muscles
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Faden procedure (recession of both medial rectus muscles and posterior fixation suture)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Slanted recession of both medial rectus muscles
Number of subjects: 28
Study: 12828501

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 5.0 mg
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 2.5 mg
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 1.0 mg
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 0.5 mg
Number of subjects: 1547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1547
Study: 10871909

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 152
Study: 9420131

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Immunotherapy
Number of subjects: 51
Study: 8508996

Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 or 16 mg once daily
Number of subjects: 307

Group type: COMPARATOR
Intervention: Nifedipine t.i.d.
Number of subjects: 307
Study: 3521557

Group type: EXPERIMENTAL
Intervention: Topical carbonic anhydrase inhibitor (aminozolamide) - 50 microL gel application
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated control eye
Number of subjects: 18
Study: 31481555

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Program (HeLP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (physiotherapy)
Number of subjects: 0
Study: 27602508

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Mini-hyperfractionated cyclophosphamide, vincristine, and doxorubicin plus inotuzumab
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: MRD negativity in S1
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: MRD negativity in S2
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in S1
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in S2
Number of subjects: 78
Study: 25341478

Group type: EXPERIMENTAL
Intervention: ARB-H (losartan 50 mg and hydrochlorothiazide 12.5 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (amlodipine 2.5 mg daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (including amlodipine 2.5 mg daily)
Number of subjects: 42
Study: 22681743

Group type: EXPERIMENTAL
Intervention: $25 shopping voucher for attending cardiovascular risk assessment
Number of subjects: 301

Group type: COMPARATOR
Intervention: No monetary incentive (control group)
Number of subjects: 301
Study: 19528204

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (12 weeks treatment)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (NGT)
Number of subjects: 94
Study: 17289483

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0.6 mg/kg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 78
Study: 12574871

Group type: EXPERIMENTAL
Intervention: Exercise training (weight bearing and resistance exercise)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exercise training + HRT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 90

Group type: COMPARATOR
Intervention: No exercise (Control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exercise training (in women not taking HRT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 90
Study: 10956570

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 8831595

Group type: EXPERIMENTAL
Intervention: albumin
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: dextran 70
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: polygeline
Number of subjects: 289
Study: 1450496

Group type: EXPERIMENTAL
Intervention: 7.7 x 10(6) I.U. of tPA (group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15 x 10(6) I.U. of tPA (group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heparin alone (group A)
Number of subjects: 30
Study: 6541387

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 50 mg p.o. twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Estriol vaginal suppositories 1 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined treatment with PPA and estriol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (initial values)
Number of subjects: 20
Study: 3781985

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (70-80 micrograms X kg‐1 X min‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 6
Study: 30238915

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 28274273

Group type: EXPERIMENTAL
Intervention: Self-myofascial release (SMR) - one session of 2×60 s at the anterior thigh
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Passive static stretching - one session of 2×60 s of passive static stretching of the anterior thigh
Number of subjects: 16

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 16
Study: 27018030

Group type: EXPERIMENTAL
Intervention: Local Anesthetic and Ketamine (LAK)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local Anesthetic Alone (LAA)
Number of subjects: 60
Study: 23983593

Group type: EXPERIMENTAL
Intervention: 0.5 µg/kg dexmedetomidine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 0.75 µg/kg dexmedetomidine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 1.0 µg/kg dexmedetomidine
Number of subjects: 132

Group type: COMPARATOR
Intervention: 0.9% normal saline (control group S)
Number of subjects: 132
Study: 20505177

Group type: EXPERIMENTAL
Intervention: RVPA shunt
Number of subjects: 549

Group type: COMPARATOR
Intervention: MBT shunt
Number of subjects: 549
Study: 18254808

Group type: EXPERIMENTAL
Intervention: LED treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated side (Control)
Number of subjects: 15
Study: 16482072

Group type: EXPERIMENTAL
Intervention: Plant sterol ester enriched margarine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Plant stanol ester enriched margarine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 41
Study: 12673257

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 80
Study: 11093999

Group type: COMPARATOR
Intervention: bupivacaine 10 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine 10 mg + fentanyl 25 microg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine 7.5 mg + fentanyl 25 microg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine 5 mg + fentanyl 25 microg
Number of subjects: 80
Study: 9420535

Group type: EXPERIMENTAL
Intervention: Narrowband UV-B
Number of subjects: 22

Group type: COMPARATOR
Intervention: Broadband UV-B
Number of subjects: 22
Study: 1543190

Group type: EXPERIMENTAL
Intervention: Hematocrit maintained at 0.35
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hematocrit maintained at 0.45
Number of subjects: 20
Study: 2859924

Group type: EXPERIMENTAL
Intervention: maytansine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: low-dose chlorozotocin (120 mg/m2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: high-dose chlorozotocin (175 mg/m2)
Number of subjects: 105
Study: 31806100

Group type: EXPERIMENTAL
Intervention: Psychiatry specialty with COI
Number of subjects: 1729

Group type: COMPARATOR
Intervention: General specialties with COI
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Desire for COI information
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Discontinuing care due to COI
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Age older than 34 years
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Educational attainment of 4 or more years of college
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Physician specialty as a psychiatrist
Number of subjects: 1729
Study: 30354990

Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (1 Hz)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation
Number of subjects: 199
Study: 27569824

Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g/L)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: L-carnitine (6 g/L)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no L-carnitine)
Number of subjects: 90
Study: 23519822

Group type: EXPERIMENTAL
Intervention: Rehmannia glutinosa acteosides (two 200‐mg capsules, bid) and irbesartan (one 150‐mg tablet, qd)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Irbesartan (one 150‐mg tablet, qd)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Both treatment and control groups
Number of subjects: 479
Study: 22854403

Group type: EXPERIMENTAL
Intervention: Intraduodenal protein load of 0.5 kcal/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraduodenal protein load of 1.5 kcal/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraduodenal protein load of 3 kcal/min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 20386016

Group type: EXPERIMENTAL
Intervention: RO5068760 50 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RO5068760 100 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RO5068760 200 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RO5068760 400 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RO5068760 600 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RO5068760 800 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RO5068760 (all doses)
Number of subjects: 48
Study: 19115449

Group type: EXPERIMENTAL
Intervention: Immediate progress feedback to therapists
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Manual-based Clinical Support Tool (CST)
Number of subjects: 1101

Group type: COMPARATOR
Intervention: 1-week delayed CST feedback
Number of subjects: 1101

Group type: COMPARATOR
Intervention: 2-week delayed CST feedback
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Delayed progress feedback and CST feedback group
Number of subjects: 1101
Study: 16306502

Group type: EXPERIMENTAL
Intervention: Plyometric training program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Basic resistance training program
Number of subjects: 27
Study: 12897739

Group type: EXPERIMENTAL
Intervention: Efalizumab (0.7 mg/kg conditioning dose followed by 7 weekly doses of 2.0 mg/kg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 11391843

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a monotherapy at a maintenance dose of 9 MIU daily for 12 months
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a monotherapy
Number of subjects: 17
Study: 8855830

Group type: EXPERIMENTAL
Intervention: Benfluorex (150 mg/tablet)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (3 tablets/day)
Number of subjects: 29
Study: 1516390

Group type: EXPERIMENTAL
Intervention: 4 ml of 2.5 percent cocaine by intratracheal injection (TI) (n = 18)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Bronchoscopic injection of cocaine (BI) (n = 19)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 4 ml of 4 percent lidocaine delivered by nebulizer (NEB) (n = 16)
Number of subjects: 53
Study: 6231942

Group type: EXPERIMENTAL
Intervention: Topical clindamycin phosphate (1% solution) twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (5% gel) twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (5% gel) in the morning and clindamycin phosphate (1% solution) in the evening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (Benzoyl peroxide and clindamycin phosphate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three regimens
Number of subjects: 0
Study: 30638771

Group type: EXPERIMENTAL
Intervention: Structured personal care (individualized multifactorial treatment)
Number of subjects: 1381

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1381

Group type: EXPERIMENTAL
Intervention: Structured personal care
Number of subjects: 1381
Study: 27890664

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rubs (ABHR) in addition to usual hand hygiene recommendations
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual hand hygiene recommendations (control group)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rubs (ABHR)
Number of subjects: 236
Study: 26092822

Group type: EXPERIMENTAL
Intervention: Combined exercise training
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Combined exercise training (in patients without previous acute myocardial infarction and diabetes microvascular complications, n=46)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (in patients without previous acute myocardial infarction and diabetes microvascular complications, n=46)
Number of subjects: 137
Study: 24456677

Group type: COMPARATOR
Intervention: Neutral table position
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 5° reverse Trendelenburg position
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 10° reverse Trendelenburg position
Number of subjects: 19
Study: 23153661

Group type: EXPERIMENTAL
Intervention: Single oral dose of green tea extract 400 mg containing 94% pure EGCG
Number of subjects: 11
Study: 19414584

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice a day (b.i.d.) for seven doses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clarithromycin 1000 mg twice a day (b.i.d.)
Number of subjects: 12
Study: 17440024

Group type: EXPERIMENTAL
Intervention: Blinded trials that reported tests for the success of blinding (31 out of 1599 trials, 2%)
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Trials that did not report tests for the success of blinding (200 trials selected randomly)
Number of subjects: 1599
Study: 14711556

Group type: EXPERIMENTAL
Intervention: Raloxifene (180 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study: 11907847

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate foam (Luxiq) twice a day for four weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate foam (Luxiq) once a day for four weeks
Number of subjects: 79
Study: 9134274

Group type: EXPERIMENTAL
Intervention: Imidapril (5 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7701055

Group type: EXPERIMENTAL
Intervention: Oxazepam (40 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oxazepam (20 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3323028

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCAA)
Number of subjects: 130
Study: 29986448

Group type: COMPARATOR
Intervention: Shooters with BLL ≥ 5 µg/dL
Number of subjects: 118

Group type: COMPARATOR
Intervention: Shooters
Number of subjects: 118

Group type: COMPARATOR
Intervention: Shooters with BLL ≥ 10 µg/dL
Number of subjects: 118
Study: 28287919

Group type: EXPERIMENTAL
Intervention: Body Project program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26423850

Group type: EXPERIMENTAL
Intervention: Polypill strategy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual medications
Number of subjects: 143
Study: 23515338

Group type: EXPERIMENTAL
Intervention: Nurse-led care programme
Number of subjects: 712

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 712
Study: 21931653

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil (single 5 mg dose)
Number of subjects: 0
Study: 19184301

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Noncontact tonometer (NCT)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Portable noncontact tonometer (PNCT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: GAT
Number of subjects: 144

Group type: COMPARATOR
Intervention: PNCT
Number of subjects: 144

Group type: COMPARATOR
Intervention: NCT
Number of subjects: 144
Study: 17540192

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/d
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 15118434

Group type: EXPERIMENTAL
Intervention: Cephalexin from day 1 after surgery to 2 days after catheter removal
Number of subjects: 101

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 101
Study: 11495620

Group type: EXPERIMENTAL
Intervention: Femoral catheterization
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Antibiotic administration via the catheter
Number of subjects: 289

Group type: COMPARATOR
Intervention: Subclavian catheterization
Number of subjects: 289
Study: 9512207

Group type: EXPERIMENTAL
Intervention: Doxapram (3.5 mg kg(‐1) bolus followed by 1 mg kg(‐1) h(‐1) infusion)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8893893

Group type: EXPERIMENTAL
Intervention: First-line paclitaxel (200 mg/m2 as a 3-hour infusion) followed by second-line doxorubicin (75 mg/m2 as a bolus injection)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Second-line doxorubicin (75 mg/m2 as a bolus injection) followed by first-line paclitaxel (200 mg/m2 as a 3-hour infusion)
Number of subjects: 330
Study: 2262219

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 0
Study: 7000105

Group type: EXPERIMENTAL
Intervention: Probenecid 0.5 g
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Probenecid 1.0 g
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Probenecid 0.5 g (without pethidine premedication)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Probenecid (without pethidine premedication, thiopentone 4 mg kg‐1)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 31280830

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (HBET)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 84
Study: 28392509

Group type: EXPERIMENTAL
Intervention: Test formulation (25-mg agomelatine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reference formulation (25-mg agomelatine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 60
Study: 25575258

Group type: EXPERIMENTAL
Intervention: Gastrografin (100 mL administered enterally)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Flavored distilled water (Control Group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 75
Study: 25889222

Group type: EXPERIMENTAL
Intervention: COBRA Slim (MTX with prednisone bridging, starting at 30 mg and tapered to 5 mg daily from week 6)
Number of subjects: 90

Group type: COMPARATOR
Intervention: MTX-TSU (15 mg of MTX weekly)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: COBRA Slim
Number of subjects: 90

Group type: COMPARATOR
Intervention: MTX-TSU
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 22489871

Group type: EXPERIMENTAL
Intervention: Palpation of bicipital tuberosities
Number of subjects: 25

Group type: COMPARATOR
Intervention: Real-time ultrasound imaging
Number of subjects: 25
Study: 21247553

Group type: EXPERIMENTAL
Intervention: Passive smoke exposure
Number of subjects: 4403

Group type: EXPERIMENTAL
Intervention: Current active smoking
Number of subjects: 4403

Group type: EXPERIMENTAL
Intervention: Increasing hours per week of passive smoke exposure
Number of subjects: 4403
Study: 18451718

Group type: EXPERIMENTAL
Intervention: almotriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: indomethacin/caffeine/prochlorperazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sumatriptan/naproxen sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAIDs (effervescent aspirin)
Number of subjects: 0
Study: 16601636

Group type: EXPERIMENTAL
Intervention: Nondrug pain management protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRU model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nondrug interventions
Number of subjects: 0
Study: 15189633

Group type: EXPERIMENTAL
Intervention: Gender differences condition (stereotype threat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No differences condition (control)
Number of subjects: 0